Category Archives: Psoriasis

More patients with moderate-to-severe psoriasis were found to be early responders to ixekizumab vs ustekinumab; all those who achieved early response were associated with stable skin clearance long-term.

Early response to the biologics ixekizumab and ustekinumab was associated with positive long-term efficacy outcomes in the treatment of moderate-to-severe psoriasis, according to study findings published in the Journal of Drugs in Dermatology.

In the management of patients with psoriasis presenting with more severe disease, researchers noted that defining and predicting high levels of clinical response, as well as identifying which patients are at risk of not having such levels, is key in tailoring treatment plans.

Although baseline Psoriasis Area Severity Index (PASI) and body mass index scores have served as modifiable predictors of response, use of these metrics has not consistently determined response to biologic therapies.

Preliminary data have shown early response to treatment is predictive of subsequent clinical improvement in patients with psoriasis, they said.

During ixekizumab treatment, patients who achieve at least a 40% improvement in PASI score (PASI 40) to at least a 50% improvement in PASI score (PASI 50) at weeks 4 and 6 often reach at least a 75% improvement in PASI score (PASI 75) at week 12 with a 90% predictability.

Seeking to further assess how early response rates to biologic therapy may predict long-term response, researchers conducted a post-hoc analysis of the IXORA-S study that compared the safety and efficacy of the interleukin (IL)-17A inhibitor ixekizumab with the IL-12/23 inhibitor ustekinumab in patients with moderate-to-severe psoriasis.

In the analysis, early treatment response rates to ixekizumab and ustekinumab were evaluated by the percentage of patients treated who achieved PASI 50 at week 2 or 4. Early response rates to these therapies were then examined for stable long-term response, as measured by associations with maintaining complete (PASI 100) or almost complete (PASI 90) skin clearance at 80% of monthly visits during weeks 16-52 of treatment.

Nonresponder imputation was used for missing PASI response status, added the study authors.

In their findings, a numerically greater number of patients given ixekizumab achieved early response vs those treated with ustekinumab; these patients were significantly more likely to achieve a stable PASI 90 response (P < .0001) or PASI 100 response (P < .0001) than the ustekinumab group.

Moreover, all patients treated with either ixekizumab or ustekinumab who were identified as early responders were more likely to achieve a stable response of PASI 90 or 100 (Odds Ratio > 1).

In patients with moderate-to-severe psoriasis treated with ixekizumab or ustekinumab, early response was a significant factor in maintaining stable complete or almost complete skin clearance, concluded the study authors. Therefore, rapid response is a clinically relevant factor to consider when optimizing individual therapeutic strategies.

Reference

Augustin M, Gallo G, See K, et al. Early response is associated with stable long-term response in psoriasis patients receiving ixekizumab or ustekinumab. J Drugs Dermatol. 2022;21(2):122-126. doi: 10.36849/jdd.6063

See the original post:
Early Response to Biologics Linked With Stable Long-term Efficacy in Psoriasis - AJMC.com Managed Markets Network

In an interview with HCPLive, Vibeke Strand, MD, MACR, FACP, Division of Immunology and Rheumatology, Stanford University, discussed her study on the effect of secukinumab in patients with active psoriatic arthritis (PsA).

The Phase 3 data displayed clinical and radiographical efficacy. Patients reported significantly sustained improvements across all dose levels compared with placebo.

This study included patients who were naive to tumor necrosis factor (TNF) inhibitor, as well as patients who were TNF-inadequate or TNF-incomplete responders.

Strand explained that patients who have been heavily treated, who are TNF-incomplete responders, might appear less improved because their scores were lower at baseline compared to patients who were TNF-naive. However, they actually reported very similar amounts of improvement.

"If you account for the fact that they're starting with lower scores because they've had the disease for longer, and they've had more failed treatments, what you can see is that actually, they're able to respond as well as a naive population," Strand said. "It's just that the baseline scores are lower."

Go here to read the rest:
Vibeke Strand, MD, on the Success of Secukinumab for Psoriatic Arthritis - MD Magazine

The research study on the Psoriatic Arthritis Therapeutics market is a detailed analysis of this industry vertical and includes substantial information like the present status of the market over the projected timeline. The basic development trends that the Psoriatic Arthritis Therapeutics market is characterized by over the forecast timeframe is provided in the report, in tandem with the vital pointers such as geographical industry layout characteristics as well as the various industry policies.

The report also includes several valuable information on the Psoriatic Arthritis Therapeutics market size, derived from various industrial sources. The report studies the competitive environment of the Psoriatic Arthritis Therapeutics industry share is based on company profiles and their efforts on increasing product value and production.

Request Sample Copy of this Report @ https://www.getnewsalert.com/request-sample/21591

Global Psoriatic Arthritis Therapeutics market forecast 2020-2026 report presents a pin-point breakdown of Industry based on type, applications, and research regions. Growth strategies adopted by these companies are studied in detail in the report. The market size section gives the Psoriatic Arthritis Therapeutics market revenues, covering both the historic growth of the market and forecasting the future.

Top Key Manufacturers in Worldwide Psoriatic Arthritis Therapeutics Market Are:

Psoriatic Arthritis Therapeutics Market Report Segment by Types:

Psoriatic Arthritis Therapeutics Market Report Segmented by Application:

Geographical Segmentation:

The study objectives of Psoriatic Arthritis Therapeutics Market report are:

Key questions answered in the Psoriatic Arthritis Therapeutics Market Report:

Request Customization on This Report @ https://www.getnewsalert.com/request-for-customization/21591

Read the original here:
Research Report and Overview on Psoriatic Arthritis Therapeutics Market, 2021-2026 - Get News Alert

This article was originally published here

Immunotherapy. 2022 Feb 14. doi: 10.2217/imt-2021-0128. Online ahead of print.

ABSTRACT

Background/aim: Multiple sclerosis (MS) is a demyelinating central nervous system disorder with few cases reported to have concomitant spondyloarthritis (SpA) spectrum disorders such as ankylosing spondylitis and psoriatic arthritis. The aim of this study is to evaluate the effectiveness of secukinumab in the treatment of MS and accompanying ankylosing spondylitis or psoriatic arthritis. Materials & methods: In addition to four cases of their own, the authors conducted a systematic literature search. Demographics, comorbidities, symptoms of MS and SpA, medical treatments and changes in clinical and laboratory findings with treatment were recorded. Results & conclusions: After secukinumab therapy, all patients were found to have treatment response regarding axial involvement, without any progression of MS observed. For both SpA spectrum diseases and MS, secukinumab may be an appropriate choice.

PMID:35152720 | DOI:10.2217/imt-2021-0128

Read this article:
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review -...

SINGAPORE A retired general practitioner was fined S$1,500 on Thursday (Feb 10) for his negligence in prescribing medication for a construction worker's psoriasis without running pre-prescription tests on the patient first.

Haridass Ramdass, 77, pleaded guilty to a single charge of endangering Savarimuthu Arul Xaviers personal safety by a negligent act. He was handed the maximum fine.

Savarimuthu died in 2014 aged 28. Haridass was originally charged with causing Savarimuthus death by a rash act, but the charge was later reduced by the prosecution.

The medication that Haridass prescribed, methotrexate, is often used in the treatment of cancer and severe psoriasis a skin disease that causes itchy and scaly patches. Methotrexate can also lead to serious and life-threatening toxic reactions.

Haridass ran Tekka Clinic Surgery on his own in the Little India area at the time, the court heard.

Around Oct 20 in 2014, Savarimuthu developed rashes over his body, face and upper and lower limbs. This prompted him to visit three different doctors to seek treatment.

At Healthway Medical Clinic in Chua Chu Kang, he was prescribed an antiseptic solution, some antihistamines and steroid cream. He went back about two weeks when he noticed his skin rashes had worsened.

He was diagnosed with psoriasis and was prescribed largely the same medication.

He then visited Bless Medical Centre in Boon Lay five days later with skin lesions on his body and limbs, which he said he had been having for months with no improvement.

He was again diagnosed with psoriasis and prescribed medication such as psoriasis oil.

On Nov 24 in 2014, he went to Haridass clinic. The doctor noted that he had extensive reddish and round lesions all over his body, including his scalp.

Savarimuthu said that his skin condition had persisted for 20 days, after which Haridass diagnosed him with psoriasis and administered an injection of Dexamethasone, which is an anti-inflammatory steroid.

Haridass also prescribed 10 tablets of methotrexate, 10 tablets of prednisolone similarly used to treat inflammation and 10 tablets of chlorpheniramine, an antihistamine.

The court heard that Haridass was negligent in failing to arrange for or ensure that Savarimuthu underwent the relevant pre-prescription tests for renal function, liver function and full blood count.

As a result, Haridass failed to discover the patients pre-existing renal impairment and was not conscious of the potentially increased toxic side effects of methotrexate.

Past court documents stated thatSavarimuthu later developed neutropenia and mucositis, leading to a fatal invasive fungal infection.

Neutropenia occurs when a person lacks a certain type of white blood cell, which helps to fight infections.Mucositis happens when a persons mouth or gut becomes sore and inflamed a common side effect of chemotherapy for cancer.

Deputy Public Prosecutors (DPPs) Timotheus Koh and Grace Chua said that methotrexate use in patients with impaired renal function should be undertaken with extreme caution as the impairment will decrease the bodys ability to eliminate the drug.

While the prosecutors noted that deaths have been reported following the use of methotrexate in the treatment of psoriasis, they also agreed with the defence not to make reference on whether Savarimuthu had suffered any adverse effect resulting from its consumption.

'GENUINELY REMORSEFUL'The prosecution sought the maximum fine, noting that the sentence must adequately deter negligence by medical professionals.

Doctors are vested with enormous responsibility and influence by their patients who, in entrusting their health and well-being to them, often accept their professional judgements unquestioningly.

This dynamic is even more pronounced in the case of foreign workers like the patient, who lack the knowledge and language ability to effectively interrogate their doctors recommendations, the prosecution added.

The risk to Savarimuthu was also of significant danger, the DPPs said. Methotrexate toxicity has been reported to cause fatal opportunistic infections, such as by fungi, which can be aggravated in patients with impaired renal function such as Savarimuthu.

In mitigation, Haridass lawyer, Senior Counsel Davinder Singh from Davinder Singh Chambers, said that there was no risk of the doctor committing the offence again as he has retired and not renewed his practising certificate.

Haridass is genuinely remorseful and accepts he was wrong, Mr Singh added in agreeing for a fine of S$1,500 to be imposed.

District Judge Eddy Tham noted that the doctor had been charged only with endangering Savarimuthus personal safety.

I will assume that none of the grave consequences (mentioned in court) had come to pass If any significant harm had resulted to the patient, in fact, I would have had no hesitation in imposing a custodial sentence, he told the court.

Those convicted can be jailed for up to three months or fined up to S$1,500, or punished with both.

CORRECTION: An earlier version of the headline implied that the patient had died because of the medication prescribed to him by the doctor. However, the prosecution and defence had agreed his death was not directly linked to the doctor's prescription. We are sorry for the error.

Read the original here:
GP fined S$1500 for negligence after giving medication to patient without pre-prescription tests - TODAY

Living with a visible condition like psoriasis can impact your physical and emotional health.

While the right psoriasis treatment plan can help you manage physical symptoms, connecting with others with this condition can help foster mental and emotional support. That support network can also be a valuable source of advice and information for how to tackle whatever life with psoriasis throws your way.

Not sure where to start your search for psoriasis support? Here are six ways to connect with others who are living with psoriasis.

Finding a local support group in your area is a great way to connect with others who have psoriasis where you live. These groups serve as a space where people meet in person to share their experiences as well as psoriasis management tips.

Local support groups are often run by a facilitator or therapist. Your dermatologist may be able to refer you to an in-person support group near you.

Online support groups give you the chance to easily interact with others who have psoriasis. It can be done from your home without arranging to meet face-to-face. This is comforting for some who wish to remain somewhat anonymous or are looking for instant support.

Online support groups also help you overcome geographic hurdles by allowing you to connect with others who have psoriasis no matter where you live.

The National Psoriasis Foundation recommends signing up with their partner, Kopa for Psoriasis, for online community support. The Psoriasis community forum run by Inspire is another option.

An alternative to group support is talking one-on-one with someone who shares the experience of living with psoriasis. A 2020 meta-analysis of studies concluded that one-on-one peer support is a great source to help with the social aspects of mental health.

If youre looking for this type of personal connection, The National Psoriasis Foundation has a One to One program that matches up people with psoriasis with a mentor. With One to One, you can sign up to receive support, or you can apply to become a mentor through the program.

Many people who are living with psoriasis share their experiences on social media platforms like Instagram or TikTok.

You can engage with these posts by following hashtags like #psoriasis, #psoriasiswarrior, and #psoriasisawareness. Through this process, you can connect with other followers who share your experiences.

Social media is another way to learn whats happening in the psoriasis community, whether near you or in other parts of the world.

The psoriasis community is large and advocates often hold awareness or fundraising events.

The National Psoriasis Foundation has a directory of these types of events on its website. You can simply attend these events as a guest, volunteer to help out, or participate in fundraising. In the process, youll get to know others who are also living with psoriasis.

Conferences are another engagement opportunity.

The National Psoriasis Foundation often hosts virtual or in-person community events. These conferences give you a chance to learn more about psoriasis.

You can also learn whats happening in the psoriasis community and connect with others who are living with the condition.

A support group, either in-person or online, should provide a sense of community where you know youre not alone with psoriasis. It can provide emotional support as well as tried-and-true advice for managing psoriasis from people who have been there.

Not every support group will be the best fit for you. Before you sign up, consider asking these questions to determine if its the right environment for you:

Perhaps the most important question to ask yourself is whether the group feels right for you.

For instance, ask yourself if youre comfortable attending a support group for psoriasis run by someone living with the condition. If not, you might prefer to search for a group thats run by a mental health professional.

A support network is an invaluable resource for anyone living with psoriasis, no matter the source.

Consider participating in support groups in a way that makes you feel comfortable. At first, that may mean just listening to others and helping them through their experience. When youre ready, you may be more willing to open up more about your own life with psoriasis.

Psoriasis can have physical and emotional tolls. It can be hard to communicate what its like to live with the condition.

Connecting with others who understand firsthand can help gain knowledge about whats worked for them all while helping you feel less alone.

Original post:
Psoriasis Support: How to Connect with Others - Healthline

(SACRAMENTO)

Taking bile acids or treatments that regulate their production levels may help control inflammation caused by psoriasis, a chronic skin condition, a UC Davis Health study has found.

Psoriasis, which causes itchy and painful scales and red patches on the skin, is linked to the bodys immune system. The study, published in the Journal of Investigative Dermatology, suggests that bile acids may treat psoriasis by stopping immune T cells from producing a proinflammatory protein known as IL-17A and blocking the immune cell movement to the inflammation site.

Our studies showed that bile acids significantly inhibited skin inflammation without causing apparent systemic adverse effects, said Sam T. Hwang, professor and chair of dermatology at UC Davis Health and senior author of the study.

Bile acids are produced in the liver and secreted into the first part of the small intestine to help digest food. While most bile acids are reabsorbed into the liver, a small portion escapes into the colon. There, they get transformed by the gut microbiota into secondary bile acids including lithocholic acid (LCA), deoxycholic acid (DCA) and 3-oxoLCA.

Bile acids are important in lipid absorption and cholesterol balance in the blood. Previous studies have identified their role as key signaling molecules in regulating skin immunity and inflammatory diseases.

Hwang and his colleagues had previously shown that proinflammatory diets, such as those rich in fats and simple sugars, greatly change the type of bacteria that reside in the gut, possibly resulting in changes to the levels of these secondary bile acids.

Interleukin-23 (IL-23) is a protein generated by the immune cells. It is responsible for many inflammatory autoimmune reactions, including psoriasis. In one of their studies, the researchers injected mice with IL-23 DNA to induce a response mimicking psoriasis-like skin disease.

They found that compared to mice receiving a placebo treatment, all the mice treated by any of the three secondary bile acids had less redness, scaling and ear thickness. The LCA bile acids showed the greatest improvement in ear swelling.

In another test, the scientists gave oral LCA to mice over two days before applying imiquimod, an immune response modifier used in treating skin diseases. They found that LCA-treated mice had less skin inflammation than those not given bile acids.

As oral LCA might cause gut reactions such as diarrhea, constipation, and stomach pain, the researchers also explored giving LCA through intravenous injection in IL-23 treated mice. Similar to LCA taken orally, an LCA injection in mice also improved psoriatic skin signs.

Previously, the researchers found that a type of receptor protein known as chemokine receptor 6 (CCR6), and its binding partner CC chemokine ligand 20 (CCL20), are linked to the inflammation caused by psoriasis. CCR6 is a critical agent for the migration of T cells a type of white blood cells to the injury site.

In this new study, the researchers found that in the IL-23 mouse model, keratinocytes (the dominant cells in the outer skin layer) served as a major source of CCL20 in the skin.

They found that LCA diminished the production of the proinflammatory protein IL-17A, prevented skin cells from producing CCL20, and blocked the development of psoriasis.

Giving bile acids or using treatments that regulate the work of bile acids may be beneficial for controlling psoriatic inflammation, said Zhenrui Shi, visiting assistant researcher in the UC Davis Department of Dermatology and co-lead author on the study. Our work provides an explanation for several prior small pilot studies of oral bile acid supplementation in psoriatic patients that resulted in improvement of their psoriasis.

Using this link, you can download the article for free, until March 24, 2022.

###

Co-authors on this study are Xuesong Wu, Mindy Huynh, Timothy Law, William Liakos, Jimmy C. Wu, Daisuke Yamada, Guiyan Yang and Yu-Jui Yvonne Wan at the University of California, Davis; Zhenrui Shi at the University of California, Davis and the Sun Yat-sen University, China; Satya Singh and Joshua M. Farber at the National Institute of Allergy and Infectious Diseases (NIAID).

This study was supported by a National Psoriasis Foundation Discovery Grant and a Guangdong Basic and Applied Basic Research Foundation (2020A1515110320).

Relevant readings:

More here:
Bile acids may improve skin inflammation in patients with psoriasis - UC Davis Health

Incidence of skin diseases such as psoriasis, melanoma, and dermatophytosis is increasing at a rapid rate. They can be more severe if not detected or diagnosed early. These diseases can spread through infection from one individual to another. For early diagnosis of these diseases, skin analysis systems are used. These systems generally include imaging, pigmentation, and other analysis tools.

Read Report Overview - https://www.transparencymarketresearch.com/skin-analysis-systems-market.html

Various factors such as increased pollution levels, changed lifestyle, and exposure to environment and variables such as UV rays are affecting the skin health of people across the world negatively. . In order to regularly check the skin health; diagnose various skin diseases and disorders; and take preventive measures, skin analysis is carried out.

Rise in the prevalence of skin diseases and increased concerns among people about their youthfulness are some of the key factors driving the global skin analysis systems market. For instance, as per the U.S. Department of Health and Human Services, more than 3.5 million people are diagnosed with skin cancer in the U.S. every year.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=57963

According to the WHO, around 3.1% adult population in the U.S. was suffering from psoriasis in 200910. Increased exposure of the skin to factors such as UV rays and chemicals, rise in pollution levels, stressful lifestyle, and increased awareness among people about skin health are other factors fueling the global skin analysis systems market. However, stringent regulations regarding product approval and increase in the demand for inexpensive products by consumers are restraining the global skin analysis systems market.

The global skin analysis systems market can be segmented based on product type, application, and region. In terms of product type, the global skin analysis systems market can be divided into skin elasticity, skin pigmentation, skin imaging, and skin condition. The skin pigmentation segment dominates the global market and is expected to maintain its position during the forecast period, owing to detailed analysis of the skin, quick diagnosis, and brilliant image quality offered by skin pigmentation devices.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=57963

The skin imaging segment is expected to expand at a significant CAGR during the forecast period, due to multiple applications of skin imaging in detecting various skin conditions and disorders. Based on application, the global skin analysis systems market can be classified into hospitals, dermatology clinics, and others. The hospitals segment is dominant and is likely to continue its dominance during the forecast period, owing to availability of multiple skin imaging options and devices in hospitals. The dermatology clinics segment is expected to expand at a high CAGR during the forecast period, due to dermatology clinics offer customized services at an affordable price.

In terms of region, the global skin analysis systems market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among regions, North America is dominant and is expected to lead the global market during the forecast period also. Rise in the prevalence of skin diseases led by increasing geriatric population and highly advanced and developed health care infrastructure in the region are major factors driving the skin analysis systems market in North America. The market in Asia Pacific is expected to expand at a high CAGR in the next few years, due to increase in awareness regarding skin care and rise in the health care expenditure.

Pre Book Skin Analysis Systems Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=57963&ltype=S

The global skin analysis systems market is highly fragmented, due to presence of a large number of companies in the market. Key players operating in the global market are Bio-Therapeutic Inc., Callegari Srl, Visiomed Group SA, Canfield Scientific, Inc., Davi & Cia, DJM Medical Instrument GmbH, BOMTECH ELECTRONICS CO., Ltd., DermoScan GmbH, CYNOSURE, and Cortex Technology.

Browse more Reports by Transparency Market Research:

Connected Drug Delivery Devices Market: Key drivers of the connected drug delivery devices market include rise in the geriatric population, increase in the incidence of chronic disease, rise in preference for injectable drug delivery, increase in demand for drugs comprising large molecules in pre-filled syringes.

Drug Delivery Technology Market: Increase in global prevalence of chronic diseases that require novel drug delivery technologies for treatment is expected to boost the market. Emergence of advanced technologies and surge in research & development activities are some factors that are expected to propel the drug delivery technology market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Original post:
Skin Analysis Systems Market: The Skin Pigmentation Segment Dominates the Global Market - BioSpace

A randomized, placebo-controlled study of 25,000 older adults found those who took vitamin D, or vitamin D and omega-3 fatty acids, had a significantly lower rate of autoimmune diseases such as rheumatoid arthritis and psoriasis compared with people who took a placebo. The study was part of the larger, nationwide VITAL trial, and the findings were published January 26 in theBMJ.

It is exciting to have these new and positive results for nontoxic vitamins and supplements preventing potentially highly morbid diseases, said the study's senior author,Karen Costenbader, MD, MPH, a professor at Harvard Medical School and the director of the lupus program at Brigham and Womens Hospital, both in Boston, in a news release.

This is the first direct evidence we have that daily supplementation may reduce autoimmune disease incidence, and what looks like a more pronounced effect after two years of supplementation for vitamin D, said Dr. Costenbader.

A normally functioning immune system helps prevent illness from infection and disease, but in a person with autoimmune disease, the immune system is too active and mistakenly attacks the bodys own cells and tissues.

There are more than 80 known autoimmune diseases, including conditions such as multiple sclerosis, lupus, rheumatoid arthritis, and type 1 diabetes. Approximately 5 to 8 percent of people more than 24 million in the United States live with an autoimmune disorder, according to the National Institute of Environmental Health Sciences (NIEHS).

Experts dont know how autoimmune diseases occur; they arent contagious. A hereditary link is present in many autoimmune conditions, and it may be that a virus or an environmental factor triggers the disease if a person already has the genes for it, per the NIEHS.

There is some evidence that certain autoimmune diseases are related to vitamin D levels, and some autoimmune conditions, such as MS, are more common in northern latitudes where vitamin D levels are, on average, lower because of low sun exposure, according to the National Multiple Sclerosis Society.

Several clinical trials, including a meta-analysis published in the Journal of Clinical Rheumatology, have found that omega-3 fatty acids taken in the form of fish oil supplements may improve the symptoms of some autoimmune diseases.

The original VITAL study was a randomized, double-blind, placebo-controlled trial of 25,871 people that observed the effects of vitamin D and omega-3 fatty acid supplementation on different types of cancer and cardiovascular disease, including heart attack and stroke. Participants were 71 percent non-Hispanic white, 20 percent Black, and 9 percent other racial or ethnic groups; 51 percent were women, and the average age was 67.1 years old.

Before the start of that trial, researchers also planned to examine whether the supplements would have any impact on how many people developed an autoimmune disease as part of an ancillary study. After a median follow-up of 5.3 years, researchers found the following results:

But the study did find evidence of an increased effect of the omega-3 fatty acid supplement after a longer duration of supplementation.

The study is fascinating, says Elizabeth Bradley, MD, the medical director of Cleveland Clinics Center for Functional Medicine in Ohio, who was not involved in this research. The researchers saw a significant decrease in the development of autoimmune disease after supplementing with vitamin D, she says.

At the Center for Functional Medicine, Dr. Bradley and a team of healthcare providers run groups for people with different types of autoimmune disorders.

These findings fit with what we see in real life; we routinely check vitamin D and omega levels in people with autoimmune diseases, and I would say 99 percent of the time, they are low in both unless they are taking a supplement already or eating a diet high in fatty fish, she says.

Although these findings make Bradley want to recommend supplements to almost everyone, she does think its a good idea to get your levels checked first. Research indicates that people whose vitamin D levels place them in the lowest quartile would likely get the most benefit from taking a supplement, she says.

To reduce the risk of autoimmune disease in women age 55 years and older and men 50 years and older, Costenbader recommends 2,000 international units (IU) ofvitamin D a day and 1,000 milligrams (mg) a day of marine omega-3 fatty acids (fish oil) the doses used in VITAL.

Its a good idea to check in with your doctor before taking supplements, says Bradley. We do have to be careful with vitamin D supplementation because it is stored in our fat and can accumulate in the body, she says. Though it isnt very common, taking very large doses could result in toxicity, according to the National Institutes of Health.

Fish oil supplements can vary in quality, says Bradley. Your provider may have suggestions on what to look for in labeling, or you can research different brands at independent websites such as ConsumerLab.com, which reviews and rates supplements.

Read more from the original source:
Vitamin D and Fish Oil Supplement May Reduce the Risk of Autoimmune Disease - Everyday Health

Symptoms can start at any age, but the first signs of psoriasis often occur between the ages of 15 and 25, according to the National Psoriasis Foundation.

When psoriasis first appears, you start to notice symptoms of inflammation on your skin. This can include:

As the condition progresses, symptoms can start to worsen or become more noticeable.

Symptoms can vary based on the type of psoriasis (well get to the seven main subtypes in a sec), the amount of psoriasis, and the area thats affected.

While psoriasis can show up anywhere on your body. It most commonly develops on your:

The features, feels, and early symptoms of psoriasis might often depend on what type you have.

Plaque psoriasis is the most common type, affecting 80 to 90 percent of people with the condition.

This form of psoriasis usually first appears as thick, raised patches of skin aka plaques. These plaques can be red, purple, or silver and often vary in size. Over time, they may start to feel dry and scaly, which can cause them to itch like crazy.

Guttate psoriasis appears as tiny bumps that may pop up suddenly on your skin. These bumps, or spots, are usually red or pink and have a scaly texture.

Guttate psoriasis often begins to show up on your arms, legs, or torso, but the condition can develop in other areas.

Guttate spots are known to clear up on their own and sometimes never make a return appearance. No one really knows why this happens, making guttate psoriasis one of the more mysterious psoriasis types.

While other forms of psoriasis are raised and rough to the touch, inverse psoriasis causes flat, raw-looking rashes in folds of the skin. These reddish or purple rashes are usually smooth to the touch, but that doesnt make them any less uncomfortable.

Inverse psoriasis usually develops in areas where skin is constantly rubbing on skin (like the armpits, under boob area, and even the genitals). This can cause increasing levels of soreness or discomfort over time especially when sweat gets trapped in these folds.

When it comes to pustular psoriasis, youll usually see puss-filled bumps often appearing on your hands and feet. These small, inflamed bumps can typically be confused for acne when they first appear.

But youll def be able to tell the difference as the condition progresses. The skin underneath the pus-filled bumps will become red and swollen. The area can also become itchy and sore.

As the bumps dry out, theyre usually replaced with scaly, brown dots.

If you start to experience symptoms of erythrodermic psoriasis, call the doctor STAT.

This rare, severe form of psoriasis can cause large chunks of skin to shed, leading to debilitating pain. It can also cause an elevated heart rate, dehydration, fever, chills, and muscle weakness. Erythrodermic psoriasis can also lead to hypothermia, making it difficult to stay warm.

Erythrodermic psoriasis spreads fast, causing visible inflammation in nearly 90 percent of your body. This condition can resemble a burn at first, with the skin becoming red, dry, and tender to the touch. You may experience intense itching as the rash spreads.

Most cases of erythrodermic psoriasis occur in people who already have another form of psoriasis. Talk with your dermatologist ASAP if you notice your condition becoming worse or not responding to treatment, as this condition can be life threatening.

Nail psoriasis affects well, your nails (obvi). Nail psoriasis is pretty common, impacting about 50 percent of people who already have another type of psoriasis.

At first, you may notice discoloration of your nails (usually yellow, white, or brownish hues), as well as pitting in your nails themselves. As the condition develops, larger dents in the nail may form, and the nail may become rough and crumbly.

Skin cells can also build up underneath your nails, causing the nail to lift and detach from the skin of your finger or toe.

Psoriatic arthritis (PsA) gets under your skin literally. This subtype affects the joints and most often occurs in people who already have psoriasis. It can develop at any age, most commonly appearing between ages 30 and 50.

Early signs of PsA can include swollen or tender joints, swelling on the knee or back of the leg, and pain on or around your heel. You may also notice stiffness, specifically in the mornings (because getting out of a cozy bed isnt hard enough sometimes!).

Its important to seek treatment for PsA. Ignoring the condition might lead to difficulty moving and even physical disability.

Originally posted here:
Early-Stage Beginning of Psoriasis: Symptoms and Types - Greatist